Aralez buys US and Canadian rights to Zontivity from Merck

08-09-2016

Aralez buys US and Canadian rights to Zontivity from Merck

Copyright © 2009-2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All rights reserved.

Aralez Pharmaceuticals has acquired the US and Canadian rights to Zontivity (vorapaxar) in an agreement with Merck.


Aralez, Zontivity, Merck, vorapaxar, drug agreement, licensing

LSIPR